샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794489

세계의 멀미약 시장

Motion Sickness Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 270 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 멀미약 시장은 2030년까지 7억 2,140만 달러에 달할 전망

2024년에 5억 9,200만 달러로 추정되는 세계의 멀미약 시장은 분석 기간인 2024-2030년에 CAGR 3.3%로 성장하며, 2030년에는 7억 2,140만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 항히스타민제는 CAGR 4.1%를 기록하며, 분석 기간 종료시에는 4억 9,010만 달러에 달할 것으로 예측됩니다. 항콜린제 부문의 성장률은 분석 기간 중 CAGR 2.0%로 추정됩니다.

미국 시장은 1억 6,130만 달러로 추정, 중국은 CAGR 6.4%로 성장 예측

미국의 멀미약시장은 2024년에 1억 6,130만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 1억 4,430만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 6.4%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.3%와 2.6%로 예측됩니다. 유럽에서는 독일이 CAGR 1.9%로 성장할 것으로 예측됩니다.

세계의 멀미약시장 - 주요 동향과 촉진요인 정리

멀미약이 여행과 의료 현장에서 널리 사용되는 이유는 무엇인가?

멀미약은 여행 중이나 시뮬레이션 중 이동으로 인한 어지러움, 메스꺼움, 구토, 식은땀 등의 증상을 예방하고 관리하기 위해 사용됩니다. 이 약물들은 중추신경계에 작용하여 내이의 신호를 차단하거나 평형감각과 관련된 경로의 과도한 자극을 억제함으로써 효과를 발휘합니다. 이 약제들은 항공, 해상, 육로 이동뿐만 아니라 수술 후 관리 및 전정 장애에도 일반적으로 사용됩니다. 멀미는 반복적이거나 예기치 않은 움직임이 있는 활동 중에 가장 빈번하게 발생하므로 움직임에 민감하게 반응하는 사람에게는 약리학적 개입이 중요합니다.

멀미약은 일반의약품과 처방약이 있으며, 경구용 정제, 경피 흡수 패치, 츄어블 정제, 액제 등이 있습니다. 널리 사용되는 약제 유형별로는 메클리딘, 디멘히드리나트 등의 항히스타민제, 스코폴라민 등의 항콜린제, 프로메타딘 등의 도파민 길항제 등이 있습니다. 치료 방법의 선택은 여행 기간, 증상의 심각성, 사용자의 내성에 따라 달라집니다. 이 약제들은 치료 효과뿐만 아니라 예방 효과도 있으며, 일상적인 사용과 일시적인 관리에도 적합합니다.

편의성과 내약성을 향상시키기 위해 제제는 어떻게 진화하고 있는가?

제조업체들은 더 긴 완화 효과, 사용 편의성, 적은 부작용을 제공하는 약물전달 시스템에 점점 더 많은 노력을 기울이고 있습니다. 며칠 동안 지속적으로 방출되는 경피 패치는 장시간의 선박 여행이나 비행기 여행에 선호되고 있습니다. 씹을 수 있는 정제나 구강붕해정제는 소아나 삼키기 어려운 환자에게 편리하게 투여할 수 있습니다. 진정 작용이 적은 제제는 특히 여행 중 주의력을 유지하고자 하는 여행객들에게 인기를 끌고 있습니다.

새로운 제품은 1세대 항히스타민제나 항콜린제에서 흔히 나타나는 구강건조증, 졸음, 눈부심 등의 부작용을 최소화하는 것을 목표로 하고 있습니다. 전정 증상과 위장 증상 모두에 대응하는 병용요법도 개발 중입니다. 또한 가상현실(VR) 체험과 같은 움직임 기반 엔터테인먼트 플랫폼의 성장으로 인해 움직임으로 인한 불편함을 줄이면서 감각의 선명도를 유지하는 비진정성 속효성 제제에 대한 새로운 수요 영역이 개발되고 있습니다.

지역별 시장 수요를 형성하는 최종사용자 동향은?

멀미약의 사용은 특히 여행이 잦은 사람, 크루즈 승객, 항공 관계자들 사이에서 많이 사용됩니다. 해외여행이 재개되면서 공항, 약국, 여행 클리닉에서 이들 의약품에 대한 수요가 회복되고 있습니다. 멀미에 취약한 어린이와 노년층은 보다 순하고 내약성이 높은 제제를 찾는 중요한 소비자층을 형성하고 있습니다. 의료계에서는 멀미약이 전정 편두통과 내이 장애의 치료 보조제로도 사용되고 있습니다.

레저 보트, 야외 관광, 놀이공원 등에서도 멀미약을 복용하는 것이 일반적으로 권장되고 있습니다. 군 및 국방 분야에서는 비행 승무원과 해군 요원의 운동 유발성 메스꺼움을 관리하는 것이 미션 크리티컬한 것으로 간주되어 장시간 작용하고 성능을 유지할 수 있는 옵션을 사용하도록 권장하고 있습니다. 이러한 최종사용자의 다양한 환경은 전 세계에서 제형 개발, 용법 선호도, 유통 전략에 지속적으로 영향을 미치고 있습니다.

멀미약 소비와 기술 혁신의 성장 원동력은?

멀미약 시장의 성장은 전 세계 여행 증가, 소비자 인식 향상, 제품 디자인 진화와 관련된 몇 가지 요인에 의해 발생합니다. 크루즈 및 모험 여행 산업의 확대로 인해 움직임이 많은 환경에서의 예방약에 대한 수요가 증가하고 있습니다. 전정장애 진단 건수 증가와 치료 접근성 향상으로 처방약의 보급에 기여하고 있습니다. 경피 흡수형 제형과 사용하기 쉬운 경구용 제형의 혁신으로 다양한 계층이 이들 제품을 쉽게 이용할 수 있게 되었습니다. 멀미약은 전자 약국, 조제 약국 등 다양한 소매 채널에서 구할 수 있으며, 제품의 인지도와 편의성이 향상되고 있습니다. 또한 비행 시뮬레이터나 VR 용도과 같이 움직임이 많은 디지털 환경을 접할 기회가 많아지면서 진정 작용이 없고 효과가 빠른 멀미약의 새로운 이용 사례가 생겨나면서 선진국과 신흥 시장의 꾸준한 성장을 지원하고 있습니다.

부문

약제 클래스별(항히스타민제, 항콜린제); 유통 채널별(오프라인 유통 채널, 온라인 유통 채널)

조사 대상 기업의 예

  • Abbott Laboratories
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bayer AG
  • BONINE(WellSpring Pharmaceutical)
  • Cipla Limited
  • CVS Health Corporation
  • GlaxoSmithKline plc(GSK)
  • Lupin Limited
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Prestige Consumer Healthcare Inc.
  • Reliefband Technologies LLC
  • Sanofi S.A.
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd
  • WellSpring Pharmaceutical Corp.
  • Zydus Lifesciences Ltd.

AI 통합

당사는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Motion Sickness Drugs Market to Reach US$721.4 Million by 2030

The global market for Motion Sickness Drugs estimated at US$592.0 Million in the year 2024, is expected to reach US$721.4 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Antihistamines, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$490.1 Million by the end of the analysis period. Growth in the Anticholinergics segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$161.3 Million While China is Forecast to Grow at 6.4% CAGR

The Motion Sickness Drugs market in the U.S. is estimated at US$161.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$144.3 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Motion Sickness Drugs Market - Key Trends & Drivers Summarized

Why Are Motion Sickness Drugs Widely Used in Travel and Medical Settings?

Motion sickness drugs are used to prevent and manage symptoms such as dizziness, nausea, vomiting, and cold sweats caused by movement during travel or simulation. These drugs work by acting on the central nervous system to block signals from the inner ear or reduce overstimulation of the balance-related pathways. They are commonly used for air, sea, and land travel as well as in post-operative care and vestibular disorders. Motion sickness is most frequently experienced during activities involving repetitive or unanticipated motion, making pharmacological intervention important for individuals with high sensitivity to movement.

These drugs are available in both over-the-counter and prescription forms, in oral tablets, transdermal patches, chewable tablets, and liquid formulations. Widely used drug classes include antihistamines such as meclizine and dimenhydrinate, anticholinergics such as scopolamine, and dopamine antagonists like promethazine. The choice of therapy depends on duration of travel, severity of symptoms, and user tolerance. These medications provide preventive as well as therapeutic relief, making them suitable for routine use and episodic management alike.

How Are Drug Formulations Evolving to Improve Convenience and Tolerability?

Manufacturers are increasingly focusing on drug delivery systems that offer extended relief, ease of use, and fewer side effects. Transdermal patches, which provide continuous release over several days, are preferred for long-duration sea or air travel. Chewable and orally disintegrating tablets offer convenient administration for children or patients with swallowing difficulties. Formulations with reduced sedative effects are gaining popularity, especially for travelers who wish to remain alert during trips.

Newer products aim to minimize dry mouth, drowsiness, and blurred vision-side effects commonly associated with first-generation antihistamines and anticholinergics. Combination therapies that address both vestibular and gastrointestinal symptoms are also under development. Additionally, the growth of motion-based entertainment platforms such as virtual reality (VR) experiences has opened a new area of demand for non-sedating, rapid-acting formulations that maintain sensory clarity while reducing motion-induced discomfort.

What End-User Trends Are Shaping Market Demand Across Regions?

Use of motion sickness drugs is particularly high among frequent travelers, cruise passengers, and aviation personnel. With the resumption of international travel, demand for these medications is rebounding across airports, pharmacies, and travel clinics. Pediatric and geriatric populations, who are often more susceptible to motion sickness, form a significant consumer base for milder, well-tolerated formulations. In healthcare settings, motion sickness medications are also used as adjuncts in treating vestibular migraines and inner ear disorders.

The leisure boating sector, outdoor adventure tourism, and ride-based amusement parks represent additional market niches where such drugs are commonly recommended. In military and defense applications, managing motion-induced nausea in flight crews and naval personnel is considered mission-critical, prompting the use of long-acting and performance-preserving options. These diverse end-user settings continue to influence formulation development, dosage preferences, and distribution strategies globally.

What Is Driving Growth in Motion Sickness Drug Consumption and Innovation?

Growth in the motion sickness drugs market is driven by several factors related to increased global travel, higher consumer awareness, and evolving product design. Expansion of the cruise and adventure tourism industry is raising demand for preventive medications in high-motion environments. Rising diagnosis of vestibular disorders and better access to treatment are contributing to prescription drug uptake. Innovation in transdermal delivery systems and user-friendly oral formats is making these products more accessible to varied demographics. The availability of motion sickness drugs through multiple retail channels, including e-pharmacies and in-transit dispensaries, is enhancing product visibility and convenience. Additionally, increased exposure to motion-heavy digital environments such as flight simulators and VR applications is creating new use cases for non-sedating, fast-acting motion sickness drugs, supporting steady growth across developed and emerging markets.

SCOPE OF STUDY:

The report analyzes the Motion Sickness Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antihistamines, Anticholinergics); Distribution Channel (Offline Distribution Channel, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Abbott Laboratories
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Bayer AG
  • BONINE (WellSpring Pharmaceutical)
  • Cipla Limited
  • CVS Health Corporation
  • GlaxoSmithKline plc (GSK)
  • Lupin Limited
  • Myungmoon Pharma Co. Ltd.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Prestige Consumer Healthcare Inc.
  • Reliefband Technologies LLC
  • Sanofi S.A.
  • Taj Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd
  • WellSpring Pharmaceutical Corp.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Motion Sickness Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth in Air, Sea, and Road Travel Increases Use of Preventive Pharmaceuticals for Motion Disorders
    • Expansion of Global Tourism and Business Travel Sustains Long-Term Demand for OTC and Prescription Options
    • Growing Consumer Awareness of Early Symptoms Encourages Proactive Use of Anti-Nausea Treatments
    • Availability of Multiple Dosage Forms Enhances User Convenience and Compliance
    • Increasing Prevalence of Motion Sickness Among Children and Elderly Supports Market Expansion
    • Advancements in Non-Drowsy and Extended-Release Formulations Drive Product Differentiation
    • Rising Demand for Natural and Herbal Remedies Opens New Avenues for Plant-Based Alternatives
    • Growth in E-Commerce and Online Pharmacies Boosts Global Access to Motion Sickness Drugs
    • Expansion of Aviation and Cruise Industries Generates Bulk Demand for In-Transit Medical Stock
    • Inclusion in Travel Health Kits and Retail Travel Accessories Increases Point-of-Sale Presence
    • Rising Need for Motion Sickness Solutions in Virtual Reality (VR) Applications Creates Emerging Use Cases
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Motion Sickness Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Motion Sickness Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antihistamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antihistamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anticholinergics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anticholinergics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Offline Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Offline Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Motion Sickness Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Motion Sickness Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Motion Sickness Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Motion Sickness Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Motion Sickness Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Motion Sickness Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Motion Sickness Drugs by Drug Class - Antihistamines and Anticholinergics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Motion Sickness Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihistamines and Anticholinergics for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Motion Sickness Drugs by Distribution Channel - Offline Distribution Channel and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Motion Sickness Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Offline Distribution Channel and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제